drugset

drugset / Trial / NCT05025631

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）

NCT05025631 ↗

Phase 2 Completed 29 enrolled Zhen-Yu Ding

NaSingle-groupOpen-labelTreatment

Summary

A Phase II study on dose optimization of fruquintinib in elderly metastatic colorectal cancer patients refractory to standard treatment.

Timeline

Start: 2020-11-06
Primary completion: 2022-10-30
Completion: 2022-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fruquintinib	Small molecule	5 mg	Oral

Indications